CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2013-06-10): FDA wants more safety data on hepatitis B vaccine

Regulatory

FDA wants more safety data on hepatitis B vaccine

Last Updated: 2013-06-10 12:40:22 -0400 (Reuters Health)

(Reuters) - Dynavax Technologies Corp said the U.S. Food and Drug Administration asked for additional safety data on its experimental hepatitis B vaccine, Heplisav.

The company said it will meet with the FDA shortly to discuss the protocol for collecting additional safety data, which it expects to include in the current approval application.

Heplisav was denied approval by the FDA in February, saying the safety data provided by the company was insufficient to support an approval.

The FDA said Dynavax's safety database needed additional subjects, the company said on Monday.

The company said it was also working on the questions raised by the FDA regarding the manufacturing and testing of Heplisav.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.